--- title: "投資者警報：Pomerantz 律師事務所代表 GeneDx Holdings Corp.的投資者進行索賠調查 - WGS" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/285634863.md" description: "Pomerantz 律師事務所正在代表 GeneDx Holdings Corp.（納斯達克：WGS）的投資者調查有關潛在證券欺詐或非法商業行為的索賠。GeneDx 最近公佈了 2026 年第一季度財務業績，顯示總收入為 1.023 億美元，但將全年收入指引下調至 4.75 億至 4.90 億美元，低於之前的 5.40 億至 5.55 億美元。此消息發佈後，GeneDx 的股價暴跌 49.20%，降至每股 34.51 美元。鼓勵投資者聯繫 Pomerantz 以獲取有關加入集體訴訟的更多信息" datetime: "2026-05-07T23:19:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285634863.md) - [en](https://longbridge.com/en/news/285634863.md) - [zh-HK](https://longbridge.com/zh-HK/news/285634863.md) --- # 投資者警報：Pomerantz 律師事務所代表 GeneDx Holdings Corp.的投資者進行索賠調查 - WGS NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether GeneDx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. **\[Click here for information about joining the class action\]** On May 4, 2026, GeneDx reported its first quarter 2026 financial results and updated its full-year outlook. Among other things, the Company disclosed total revenue of $102.3 million, exome and genome revenue of $90.6 million, and exome and genome test volume growth of 34% year-over-year. Despite this strong volume growth, GeneDx disclosed that exome and genome revenue increased only 27% year-over-year. The Company also reduced its full-year 2026 revenue guidance to $475 million to $490 million, compared to prior guidance of $540 million to $555 million, and reduced its expected growth in exome and genome revenue to at least 20%, compared to prior guidance of 33% to 35%. During the associated earnings call, GeneDx further disclosed that total revenue was approximately $12 million below expectations, including approximately $5.5 million due to a lower-than-expected blended average reimbursement rate for exome and genome testing, and approximately $6.5 million due to softer-than-expected performance from non-core business lines. On this news, GeneDx's stock price fell $33.42 per share, or 49.20%, to close at $34.51 per share on May 5, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. **CONTACT: **Danielle Peyton Pomerantz LLP dpeyton@pomlaw.com 646-581-9980 ext. 7980 View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-genedx-holdings-corp---wgs-302766315.html SOURCE Pomerantz LLP ### 相關股票 - [WGS.US](https://longbridge.com/zh-HK/quote/WGS.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [IDNA.US](https://longbridge.com/zh-HK/quote/IDNA.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [WGSWW.US](https://longbridge.com/zh-HK/quote/WGSWW.US.md) ## 相關資訊與研究 - [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md) - [川普投資組合神操作？Medicare 政策翻盤前 精準大買聯合健康](https://longbridge.com/zh-HK/news/287039034.md) - [復宏漢霖：注射用 HLX43 用於治療晚期非小細胞肺癌的國際多中心 2 期臨牀研究完成首例患者給藥](https://longbridge.com/zh-HK/news/287195179.md) - [儲局會議記錄顯示 大多數官員警告通脹率若持續高於 2% 需考慮加息](https://longbridge.com/zh-HK/news/287171073.md) - [Liminatus Pharma 宣佈擬與 InnocsAI 合併，以擴展其腫瘤細胞治療產品線 | LIMN 股票新聞](https://longbridge.com/zh-HK/news/287218720.md)